J Horti

6.0k total citations · 1 hit paper
17 papers, 4.6k citations indexed

About

J Horti is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, J Horti has authored 17 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in J Horti's work include Prostate Cancer Treatment and Research (7 papers), Testicular diseases and treatments (3 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). J Horti is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Testicular diseases and treatments (3 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). J Horti collaborates with scholars based in Hungary, United States and United Kingdom. J Horti's co-authors include A Płużańska, Christine Théodore, Nicholas D. James, William R. Berry, Ian F. Tannock, Mario A. Eisenberger, Ingela Turesson, Mark Rosenthal, Stéphane Oudard and Ronald de Wit and has published in prestigious journals such as New England Journal of Medicine, Nature Biotechnology and British Journal of Cancer.

In The Last Decade

J Horti

15 papers receiving 4.5k citations

Hit Papers

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone... 2004 2026 2011 2018 2004 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
    2004 4.3k citations Ian F. Tannock, Ronald de Wit et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J Horti Hungary 9 3.6k 1.6k 1.2k 1.1k 1.0k 17 4.6k
William R. Berry United States 11 3.9k 1.1× 1.8k 1.1× 1.3k 1.1× 1.1k 1.0× 985 1.0× 22 4.9k
Matthew M. Cooney United States 24 3.6k 1.0× 1.8k 1.1× 1.1k 1.0× 1.1k 1.0× 1.0k 1.0× 86 5.2k
Ivo Kocák Czechia 13 2.5k 0.7× 1.4k 0.9× 937 0.8× 798 0.7× 724 0.7× 41 3.3k
Susan Feyerabend United Kingdom 21 3.2k 0.9× 1.0k 0.6× 1.0k 0.9× 1.1k 1.0× 726 0.7× 71 3.9k
Liji Shen United States 16 2.8k 0.8× 1.3k 0.8× 1.1k 1.0× 946 0.9× 620 0.6× 37 3.5k
Simon Chowdhury United Kingdom 29 4.0k 1.1× 1.4k 0.8× 1.3k 1.1× 1.4k 1.3× 1.0k 1.0× 199 5.1k
Jean-Pascal Machiels Belgium 18 2.4k 0.7× 2.0k 1.3× 1.0k 0.9× 848 0.8× 960 0.9× 36 4.5k
Dingwei Ye China 26 3.9k 1.1× 1.1k 0.7× 1.3k 1.1× 1.6k 1.4× 958 0.9× 135 5.0k
Nobuaki Matsubara Japan 28 3.5k 1.0× 2.3k 1.4× 1.4k 1.2× 1.1k 1.1× 878 0.9× 233 5.6k
Peter De Porre United States 26 2.5k 0.7× 761 0.5× 893 0.8× 854 0.8× 730 0.7× 91 3.4k

Countries citing papers authored by J Horti

Since Specialization
Citations

This map shows the geographic impact of J Horti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Horti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Horti more than expected).

Fields of papers citing papers by J Horti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Horti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Horti. The network helps show where J Horti may publish in the future.

Co-authorship network of co-authors of J Horti

This figure shows the co-authorship network connecting the top 25 collaborators of J Horti. A scholar is included among the top collaborators of J Horti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Horti. J Horti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Horti, J, Anders Widmark, Arnulf Stenzl, et al.. (2009). A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals. 24(2). 175–180. 39 indexed citations
2.
Horti, J, et al.. (2008). Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 62(1). 173–180. 18 indexed citations
3.
Horti, J, Anders Widmark, Ingela Turesson, et al.. (2008). A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II STUDY OF VANDETANIB PLUS DOCETAXEL / PREDNISOLONE IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER. European Urology Supplements. 7(3). 231–231.
4.
Tenke, Péter, J Horti, Péter Bálint, & Béla Kovács. (2007). Prostate Cancer Screening. PubMed. 175. 65–81. 16 indexed citations
5.
Ostoros, Gyula, et al.. (2006). Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programme.. PubMed. 25(6C). 4759–62. 3 indexed citations
6.
Tannock, Ian F., Ronald de Wit, William R. Berry, et al.. (2004). Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. New England Journal of Medicine. 351(15). 1502–1512. 4338 indexed citations breakdown →
7.
Eckhardt, S. Gail, Zsuzsanna Pápai, G. Bodoky, et al.. (2003). [Effect of imatinib treatment of gastrointestinal stromal tumors].. PubMed. 144(45). 2207–12. 4 indexed citations
8.
Horti, J, Shannon C. Dixon, C. Logothetis, et al.. (1999). Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. British Journal of Cancer. 79(9-10). 1588–1593. 23 indexed citations
9.
10.
Horti, J, et al.. (1999). Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.. PubMed. 46(2). 117–23. 4 indexed citations
11.
Senderowicz, Adrian M., Robert Reid, Donna Headlee, et al.. (1999). A Phase II Trial of Gallium Nitrate in Patients with Androgen-Metastatic Prostate Cancer. Urologia Internationalis. 63(2). 120–125. 11 indexed citations
12.
Dixon, Shannon C., et al.. (1998). Methods for extracting and amplifying genomic DNA isolated from frozen serum. Nature Biotechnology. 16(1). 91–94. 35 indexed citations
13.
Horti, J, William D. Figg, Birgit Weinberger, David Köhler, & Oliver Sartor. (1998). A phase II study of bromocriptine in patients with androgen-independent prostate cancer.. Oncology Reports. 5(4). 893–6. 23 indexed citations
14.
15.
Bodrogi, I., et al.. (1994). [Review of drugs used in the neutropenic period following cytostatic therapy and comparative study of doxycycline and ofloxacin in the treatment of patients with testicular cancer].. PubMed. 135(51). 2815–9. 1 indexed citations
16.
Bodrogi, I., et al.. (1994). Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours.. PubMed. 50(3-4). 275–92. 2 indexed citations
17.
Bodrogi, I., et al.. (1990). Vinblastine, cisplatin and bleomycin treatment of advanced nonseminomatous testicular tumors.. PubMed. 37(4). 445–50.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William R. Berry Breakdown of academic impact, for papers by Matthew M. Cooney Breakdown of academic impact, for papers by Ivo Kocák Breakdown of academic impact, for papers by Susan Feyerabend Breakdown of academic impact, for papers by Liji Shen Breakdown of academic impact, for papers by Simon Chowdhury Breakdown of academic impact, for papers by Jean-Pascal Machiels Breakdown of academic impact, for papers by Dingwei Ye Breakdown of academic impact, for papers by Nobuaki Matsubara Breakdown of academic impact, for papers by Peter De Porre
Rankless by CCL
2026